Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

13.39 +1.18 (+9.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,876
Open 13.12
Bid (Size) 13.22 (1)
Ask (Size) 13.65 (4)
Prev. Close 12.21
Today's Range 12.60 - 13.60
52wk Range 7.390 - 21.28
Shares Outstanding 864,775,340
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Stocks Reacting To April PCE: Marvell Technology Leads The Rally
 
Via Benzinga
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From HUTCHMED (China) Limited
Via GlobeNewswire

Performance

YTD
-18.25%
-18.25%
1 Month
-10.97%
-10.97%
3 Month
-14.77%
-14.77%
6 Month
+12.62%
+12.62%
1 Year
+40.06%
+40.06%

More News

Read More
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Board of Directors and Board Committee Membership
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
Intended Retirement of Independent Non-executive Director
From HUTCHMED (China) Limited
Via GlobeNewswire
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Via Talk Markets
Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is HUTCHMED Stock Trading Higher Today?
Via Benzinga
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
From HUTCHMED (China) Limited
Via GlobeNewswire
Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.